KLRS
カラリス・セラピューティクス
KLRS
カラリス・セラピューティクス
Abbott Cooper PLLC is investigating fiduciary duty claims for Kalaris Therapeutics (formerly AlloVir) holders who owned shares before November 7, 2024.
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts